Accutar Biotech

accutarbio.com →

-56%

est. 2Y upside i

HealthcareSeries C

Rank

#2755

Sector

Drug Discovery

Est. Liquidity

~4Y

Data Quality

Data: Medium

Accutar Biotech presents a moderate upside opportunity for a job seeker, driven by its promising clinical pipeline, particularly the FDA Fast Track designated AC699, and a validated AI drug discovery platform.

Last updated: March 10, 2026

Bull (30%)+150%

AC699's strong Phase 1 data translates into compelling Phase 2 results, particularly for ESR1-mutated patients, accelerating its path to market. Simultaneously, AC0676 and AC0176 demonstrate promising early clinical efficacy, validating Accutar's AI platform and leading to a significant pharmaceutical partnership or a successful IPO at a valuation exceeding $1.15B.

Base (35%)+10%

AC699 progresses through Phase 2 with solid but not groundbreaking results, while other pipeline assets advance steadily. The company continues to secure moderate funding rounds and partnerships, maintaining its competitive position but not achieving a rapid, high-multiple exit. Valuation reaches approximately $507M.

Bear (35%)-50%

AC699 faces clinical setbacks or fails to differentiate significantly from competitors in Phase 2. Other pipeline programs encounter delays or efficacy issues. The high capital intensity of drug development, coupled with an inability to secure favorable funding, leads to a down round or an acquisition at a valuation around $230M, severely impacting common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Investors hold $207M in liquidation preferences. In an exit at the current ~$461M valuation, common shareholders would receive approximately $254M.

Dilution Risk

high

Clinical-stage biotechs require substantial capital for trials, making significant future funding rounds highly probable and leading to further dilution.

Secondary Liquidity

limited

While secondary markets like Forge exist, direct access for all employees is typically limited and restricted to accredited investors.

Questions to Ask at the Interview

Strategic questions based on Accutar Biotech's data — designed to show you've done your homework.

  • 1

    “Given the promising Phase 1 data for AC699 and its Fast Track designation, what are the key milestones and challenges anticipated for its Phase 2 development, and how is Accutar positioned to address them?”

  • 2

    “With multiple chimeric degrader programs in the clinic (AC699, AC0676, AC0176), how does Accutar prioritize its pipeline, and what is the strategy for funding these capital-intensive clinical trials through to commercialization or partnership?”

  • 3

    “Considering the significant capital raised to date and the current valuation, how does Accutar envision the path to a liquidity event for employees, and what measures are in place to mitigate the impact of liquidation preferences on common stock holders?”

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.